Mapping out the mystery of blood stem cells – Newswise
Posted: November 26, 2020 at 2:51 am
Newswise Princess Margaret scientists have revealed how stem cells are able to generate new blood cells throughout our life by looking at vast, uncharted regions of our genetic material that hold important clues to subtle biological changes in these cells.
The finding, obtained from studying normal blood, can be used to enhance methods for stem cell transplantation, and may also shed light into processes that occur in cancer cells that allow them to survive chemotherapy and relapse into cancer growth many years after treatment.
Using state-of-the art sequencing technology to perform genome-wide profiling of the epigenetic landscape of human stem cells, the research revealed important information about how genes are regulated through the three-dimensional folding of chromatin.
Chromatin is composed of DNA and proteins, the latter which package DNA into compact structures, and is found in the nucleus of cells. Changes in chromatin structure are linked to DNA replication, repair and gene expression (turning genes on or off).
The research by Princess Margaret Cancer Centre Senior Scientists Drs. Mathieu Lupien and John Dick is published in Cell Stem Cell, Wednesday, November 25, 2020.
We dont have a comprehensive view of what makes a stem cell function in a specific way or what makes it tick, says Dr. Dick, who is also a Professor in the Department of Molecular Genetics, University of Toronto.
Stem cells are normally dormant but they need to occasionally become activated to keep the blood system going. Understanding this transition into activation is key to be able to harness the power of stem cells for therapy, but also to understand how malignant cells change this balance.
Stem cells are powerful, potent and rare. But its a knifes edge as to whether they get activated to replenish new blood cells on demand, or go rogue to divide rapidly and develop mutations, or lie dormant quietly, in a pristine state.
Understanding what turns that knifes edge into these various stem cell states has perplexed scientists for decades. Now, with this research, we have a better understanding of what defines a stem cell and makes it function in a particular way.
We are exploring uncharted territory, says Dr. Mathieu Lupien, who is also an Associate Professor in the Department of Medical Biophysics, University of Toronto. We had to look into the origami of the genome of cells to understand why some can self-renew throughout our life while others lose that ability. We had to look beyond what genetics alone can tell us.
In this research, scientists focused on the often overlooked noncoding regions of the genome: vast stretches of DNA that are free of genes (i.e. that do not code for proteins), but nonetheless harbour important regulatory elements that determine if genes are turned on or off.
Hidden amongst this noncoding DNA which comprise about 98% of the genome - are crucial elements that not only control the activity of thousands of genes, but also play a role in many diseases.
The researchers examined two distinct human hematopoietic stem cells or immature cells that go through several steps in order to develop into different types of blood cells, such as white or red blood cells, or platelets.
They looked at long-term hematopoietic stem cells (HSCs) and short-term HSCs found in the bone marrow of humans. The researchers wanted to map out the cellular machinery involved in the dormancy state of long-term cells, with their continuous self-renewing ability, as compared to the more primed, activated and ready-to-go short-term cells which can transition quickly into various blood cells.
The researchers found differences in the three-dimensional chromatin structures between the two stem cell types, which is significant since the ways in which chromatin is arranged or folded and looped impacts how genes and other parts of our genome are expressed and regulated.
Using state-of-the-art 3D mapping techniques, the scientists were able to analyze and link the long-term stem cell types with the activity of the chromatin folding protein CTCF and its ability to regulate the expression of 300 genes to control long-term, self-renewal.
Until now, we have not had a comprehensive view of what makes a stem cell function in a particular way, says Dr. Dick, adding that the 300 genes represent what scientists now think is the essence of a long-term stem cell.
He adds that long-term dormant cells are a protection against malignancy, because they can survive for long periods and evade treatment, potentially causing relapse many years later.
However, a short-term stem cell that is poised to become active, dividing and reproducing more quickly than a long-term one, can gather up many more mutations, and sometimes these can progress to blood cancers, he adds.
This research gives us insight into aspects of how cancer starts and how some cancer cells can retain stem-cell like properties that allow them to survive long-term, says Dr. Dick.
He adds that a deeper understanding of stem cells can also help with stem cells transplants for the treatment of blood cancers in the future, by potentially stimulating and growing these cells ex vivo (out of the body) for improved transplantation.
The research was supported by The Princess Margaret Cancer Foundation, Ontario Institute for Cancer Research, Canadian Institutes for Health Research (CIHR), Medicine by Design, University of Toronto, Canadian Cancer Society Research Institute, and the Terry Fox Research Institute.
Competing Interests
Dr. John Dick served on the SAB at Trillium Therapeutics, and has ownership interest (including patents) in Trillium Therapeutics. He also reports receiving a commercial research grant from Celgene.
About Princess Margaret Cancer Centre
Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education at UHN. All are research hospitals affiliated with the University of Toronto. For more information: http://www.theprincessmargaret.ca
See the original post:
Mapping out the mystery of blood stem cells - Newswise
- Unlocking The Unlimited Potential Of Stem Cells - CodeBlue - January 9th, 2021
- Hemostemix steps into the new year with capital and its critical clinical study data in hand - InvestorIntel - January 9th, 2021
- Global Organ and Tissue Transplantation and Alternatives Market to 2024 - Impact Analysis of COVID-19 - Yahoo Finance - January 9th, 2021
- Top 10 ALS Stories of 2020 - ALS News Today - January 9th, 2021
- Brave West Lothian women discovers back pain is actually deadly blood cancer - Daily Record - January 9th, 2021
- Global Bone Marrow Aspirate Concentrates (BMAC) Market : Industry Analysis and forecast (2019 to 2026): By product Type, Application, End Users, and... - January 9th, 2021
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire - December 22nd, 2020
- Organ and Tissue Transplantation and Alternatives - GlobeNewswire - December 22nd, 2020
- How Researchers Are Making Do in the Time of COVID-19 - The Wire Science - December 22nd, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 22nd, 2020
- Priming the Immune System to Fight Cancer - PRNewswire - December 22nd, 2020
- The 11 most mind-blowing, awe-inspiring health discoveries and innovations of 2020 - Business Insider - Business Insider - December 22nd, 2020
- Orchard Therapeutics Receives EC Approval for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) - GlobeNewswire - December 22nd, 2020
- Creative Medical Technology Stock Price Increased 80.77%: Why It Happened - Pulse 2.0 - December 22nd, 2020
- Digenic mutations in ALDH2 and ADH5 impair formaldehyde clearance and cause a multisystem disorder, AMeD syndrome - Science Advances - December 22nd, 2020
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - KPVI News 6 - December 16th, 2020
- Novel class of targeted cancer therapies could treat myeloid leukaemias - Drug Target Review - December 16th, 2020
- 1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive - NPR - December 16th, 2020
- Bone Regeneration Material Market: Cell-based Segment to Expand Significantly - BioSpace - December 16th, 2020
- Shingles: What triggers this painful, burning rash? - Harvard Health Blog - Harvard Health - December 16th, 2020
- Impact of Covid-19 On Orthopedic Regenerative Medicine Market Business Overview and Forecast to 2027 | Curasan, Inc., Carmell Therapeutics... - December 16th, 2020
- Early Signs of Activity and Tolerability Found in Allogeneic Product UCART22 for Patients with Relapsed/Refractory CD22+ B-Cell ALL - Cancer Network - December 16th, 2020
- Updated Findings Show Continued Efficacy for CAR T-Cell Therapy in Heavily Pretreated Myeloma - Targeted Oncology - December 16th, 2020
- Haywards Heath woman's bid to fund stem cell treatment to combat MS - Mid Sussex Times - December 16th, 2020
- Stem Cell Transplant Reduces Relapses and Disability in RRMS... - Multiple Sclerosis News Today - December 11th, 2020
- Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start BLA Submission... - December 11th, 2020
- Groundbreaking Trial On Children With Brain Injuries In Madrid - Euro Weekly News - December 11th, 2020
- Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting - Yahoo Finance - December 11th, 2020
- Antileukemic Activity Seen With Flotetuzumab in Primary Induction Failure, Early-Relapse AML - Hematology Advisor - December 11th, 2020
- SNUH finds way to produce T-cells to prevent HSCT complications - Korea Biomedical Review - December 11th, 2020
- CLL patients in England to get AZ's Calquence after okay from NICE - - pharmaphorum - December 11th, 2020
- JP Duminy goes to bat for the SA Bone Marrow Registry - IOL - December 10th, 2020
- Donor Stem Cell Transplant Improves Survival in Older Patients with Myelodysplastic Syndrome - Cancer Health Treatment News - December 10th, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - Business Wire - December 10th, 2020
- Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID... - December 10th, 2020
- Bid to fund stem cell treatment in Mexico for woman with MS - Bournemouth Echo - December 10th, 2020
- The Technology Behind Bone Marrow Cellular Processing: The PXP System - Marketscreener.com - December 10th, 2020
- ElevateBio's HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting - Business Wire - December 10th, 2020
- Gene Therapy, Absolutely and For Real | In the Pipeline - Science Magazine - December 10th, 2020
- Negrin Shines Light on the Orca-T Story in GVHD - OncLive - December 10th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - PRNewswire - December 10th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 10th, 2020
- Hadassah Medical Center and Neurogenesis Announce Groundbreaking Results from a Phase 2 Study in Progressive Multiple Sclerosis treated with NG-01... - December 10th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 10th, 2020
- Venetoclax/Azacitidine Combination Efficacious for the Treatment of Older Patients With Higher-Risk Myelodysplastic Syndrome - Oncology Nurse Advisor - December 10th, 2020
- Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T at the 62nd ASH Annual Meeting... - December 10th, 2020
- BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium - BioSpace - December 10th, 2020
- Joliet 2-year-old gets pre-holiday gift: tests that show he's cancer-free - The Herald-News - December 10th, 2020
- Preliminary Results from NexImmune's Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition - GlobeNewswire - December 10th, 2020
- How do you donate stem cells? Donating cells can help treat cancer, blindness and other conditions - heres how - The Scotsman - December 4th, 2020
- Repairing the Brain With Stem Cells? A Conversation With Prof. Jack Price - Being Patient - December 4th, 2020
- Treatment to restore vision by injecting stem cells into the eye could help people with damaged eyesight - iNews - December 4th, 2020
- Sphingosine 1-phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated... - December 4th, 2020
- Cancer center is a contributor to 49 research studies at the 62nd American Society of Hematology Annual Meeting - Newswise - December 4th, 2020
- IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bios Gamma Delta T-cell product... - December 4th, 2020
- Bone Marrow Transplant Market Size, Segmented by Type of Deployment, Application, And Region Growth, Trends, And Forecast - The Haitian-Caribbean... - December 4th, 2020
- Gut bacteria can help rebuild the immune system - Medical News Today - December 4th, 2020
- InvestmentPitch Media Video Discusses Hemostemix Successfully Obtaining all Clinical Trial Data and Announcement of $2.5 Million Unit Offering - Video... - December 4th, 2020
- Outlook on the Multiple Myeloma Drugs Global Market to 2025 - by Therapy, Drug Type, End-user, Distribution Channel and Region -... - December 4th, 2020
- Imago BioSciences Expands Phase 2 Clinical Trial of Bomedemstat (IMG-7289) for the Treatment of Myelofibrosis into Hong Kong - Business Wire - December 4th, 2020
- The New Coronavirus Vaccine Is Changing The Future Of Medicine - Forbes - December 4th, 2020
- Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous... - November 30th, 2020
- How are bones and the heart connected? - British Heart Foundation - November 30th, 2020
- Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine - BioSpace - November 30th, 2020
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market 2020 Impact of COVID-19, Future Growth Analysis and Challenges | Regen Biopharma Inc,... - November 30th, 2020
- Coronavirus Updates: The Latest Treatments and Vaccines - GovTech - November 30th, 2020
- Hematopoietic Stem Cell Transplantation (HSCT) Market To Witness Huge Growth By 2027 | Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc,... - November 30th, 2020
- Bone Marrow Processing Systems Market Top Participant to Focus on Regional Expansion - Murphy's Hockey Law - November 30th, 2020
- Family 'over the moon' as nine-year-old Aurora confirmed as being back in remission - The Isle of Thanet News - November 30th, 2020
- Pilot study finds potential signal indicative of loss of tone in blood vessels after cardiac surgery - The Hindu - November 30th, 2020
- Family's joy as schoolgirl, 9, back in remission - Kent Online - November 30th, 2020
- Family's heartache after Hebburn boy diagnosed with one in a million condition - Chronicle Live - November 30th, 2020
- Raleigh man delivers stem cells to patients around the world - WRAL.com - November 28th, 2020
- US FDA Approves Naxitamab for the Treatment of Neuroblastoma - OncoZine - November 28th, 2020
- The roles bone marrow plays in the body - Therogersvillereview - November 27th, 2020
- Severe Infections Wreak Havoc on Mouse Blood Cell Production - Technology Networks - November 27th, 2020
- Revenue from the Sales of Hematopoietic Stem Cells Transplantation Market to Witness Relatively Significant Growth During 2017 2025 - Canaan Mountain... - November 27th, 2020
- Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for... - November 27th, 2020
- Meet 'Iron Boy': Hempfield Twp. boy fighting cancer is real superhero - Gettysburg Times - November 27th, 2020
- G1 Therapeutics: Depressed Price Before Catalyst, No Apparent Reason - Seeking Alpha - November 27th, 2020